Familial isolated growth hormone deficiency (IGHD) may result from mutations in the human GH gene (GH1), GHRH receptor gene (GHRHR), and more rarely from heterozygous mutations in HESX1 or SOX3. Mutations in the growth hormone releasing hormone receptor (GHRHR) gene are a relatively rare cause of IGHD. Aim of the present study was to understand the biochemical basis of hypoglycaemia in the index case and the molecular basis of severe short stature in a large consanguineous family with IGHD.
We describe a large consanguineous Turkish kindred with multiple members affected with a novel homozygous missense GHRHR mutation. The index case who presented with hypoglycaemic convulsion, is the first description of hypoglycaemia with GHRHR mutation to date. A marked AP hypoplasia was observed in all affected members from subfamily-1, whereas, affected patients from subfamily-2 had normal or borderline AP sizes. Two affected individuals from subfamily-1 displayed anterior pituitary hypoplasia at the very young ages of 0.4 and 2.3 years. Another interesting observation was the striking difference in auxological and biochemical severity between the two families despite identical GHRHR mutation. We suspect this difference in phenotype may be due to the effect of other unknown modifier genes.
Patients :
The index case presented with a hypoglycaemic (blood glucose 1.2 mmol/l) convulsion at the age of 2.3 years. He was born to consanguineous normal height parents at 40 weeks gestation with birth weight of 2.2 kg (<-2 SD). There was no significant medical history. On examination, his weight was 10 kg (-2.68 SD) and height was 73.2 cm (-5.01 SD). Family history revealed three siblings with severe short stature (Table 1) . Hypoglycaemic screen showed undetectable serum insulin level (< 2mU/l), a satisfactory ketogenic (β-hydroxybutyrate 1.7mmol/l) and serum cortisol response (35.7μg/dl), and an unsatisfactory GH response (0.5ng/ml). Measurement of serum insulin-like growth factor 1 (IGF1) and IGF binding protein 3 (IGFBP3), and GH provocation testing (Clonidine and L-Dopa stimulation tests) confirmed GH deficiency. Other investigations (serum ammonia, lactate, carnitines, acylcarnitines and serum amino acids) looking for other causes of hypoglycaemia were normal. Following the diagnosis of the index case, other members of the family (family 1) were evaluated for GH deficiency (Table 1) . Interestingly, another consanguineous family very closely related to this family ( Figure 1 ) also had multiple members with short stature without associated clinical features (Table 1 ). All other affected members underwent baseline investigations for short stature including full blood count, erythrocyte sedimentation rate, blood biochemistry, liver and renal function tests, coeliac screen, thyroid function tests, serum IGF1 and IGFBP3. All these investigations were within normal range apart from serum IGF1 and IGFBP3, which were significantly below the normal range for age and sex (Table 1) . Monitoring of growth over 6 months revealed low height velocity in all affected members (Table 1 ). All affected individuals showed a more than two-fold improvement in pre-treatment height velocity in response to recombinant GH therapy (0.03 mg/kg/d) ( Table 1) . Hypoglycaemia in the index case resolved after the GH was started. Hormonal Studies and Pituitary imaging: All affected members of these two families underwent two GH provocation tests (L-Dopa and Clonidine tests) on separate days according to standard guidelines. Periodic assessment of other pituitary functions such as early morning cortisol, thyroid functions, and gonadotropins was also performed until the confirmation of underlying genetic diagnosis. An MRI scan of the pituitary gland of each GHD patient was independently reviewed by two experienced neuro-radiologists for anterior pituitary hypoplasia and position of posterior pituitary bright spot. Measurements of anterior pituitary were compared to age adjusted normal values. Homozygosity mapping: Homozygosity mapping (HZM) was performed on two affected and one unaffected individual from each of the two families to identify potential candidate genes. The Illumina microarray platform was used for the genotyping following the Infinium HD Ultra Assay protocol (Rev B, 2010, Illumina Inc, San Diego, USA). The copy number variation and loss of heterozygosity data was generated using the Illumina Genomestudio software (cnvPartition v3.1.6, Illumina). The BEDtools were used for subsequent analysis of the homozygosity mapping data GHRHR sequencing: All the 13 exons of GHRHR gene were PCR amplified and sequenced in two affected patients (one from each family) using the BigDye Terminator v 1.1 Cycle sequencing kit (Applied Biosystems, Foster City, California) according to manufacturer's instructions. Any deviations from reference sequence were checked in dbSNP database, 1000 Genomes Project and Exome Variant Server. The identified variant was subsequently screened in other family members to analyse for co-segregation with disease phenotype. In silico analysis of the identified variant was performed using various software programs such as PolyPhen 2, MutationTaster and Provean. The protein BLAST tool from the NCBI (National Centre for Biotechnology information) website was used to analyse the conservation of the amino acid of interest amongst species. The UniProt database was used to localise the mutation within the protein. 
